Methods of treatment with elinzanetant
AssigneesBayer Consumer Care AG, Emerald Lake Safety LLC
InventorsMichael Block, Stefan Willmann, Alexander Solms, Annika Ruth Patricia Schneider, Marcus-Hillert Schultze-Mosgau
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating vasomotor symptoms in a female subject in need thereof by administering a therapeutically effective amount of elinzanetant or a pharmaceutically acceptable salt or deuterated thereof, wherein the female subject is concurrently administered with a moderate CYP3A4 inhibitor.
Claims27
A method of treating vasomotor symptoms in a female subject in need thereof, comprising administering a daily dose of about 25 mg to about 100 mg of elinzanetant or stereoisomer thereof, or an equivalent dose of a pharmaceutically acceptable salt or deuterated form thereof,
- wherein the female subject is undergoing concomitant treatment with a moderate CYP3A4 inhibitor.
Dependencies are inferred from the claim text.